Sonodynamic Therapy Complements PD-L1 Immune Checkpoint Inhibition in a Murine Model of Pancreatic Cancer

被引：0
|
作者：
Nesbitt, Heather [1 ]
Logan, Keiran [1 ]
Thomas, Keith [1 ]
Callan, Bridgeen [1 ]
Gao, Jinhui [1 ]
Mc Kaig, Thomas [1 ]
Taylor, Mark [2 ]
Love, Mark [3 ]
Stride, Eleanor [4 ]
Mc Hale, Anthony [1 ]
Callan, John [1 ]
机构：
[1] Ulster Univ, Coleraine, Londonderry, North Ireland
[2] Mater Hosp, Belfast, Antrim, North Ireland
[3] Royal Victoria Hosp, Belfast, Antrim, North Ireland
[4] Univ Oxford, Oxford, England
来源：
BRITISH JOURNAL OF SURGERY | 2021年 / 108卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
O-P04
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Sonodynamic therapy complements PD-L1 immune checkpoint inhibition in a murine model of pancreatic cancer
    Nesbitt, Heather
    Logan, Keiran
    Thomas, Keith
    Callan, Bridgeen
    Gao, Jinhui
    McKaig, Thomas
    Taylor, Mark
    Love, Mark
    Stride, Eleanor
    McHale, Anthony P.
    Callan, John F.
    CANCER LETTERS, 2021, 517 : 88 - 95
  • [2] PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy
    Dermani, Fatemeh K.
    Samadi, Pouria
    Rahmani, Golebagh
    Kohlan, Alisa K.
    Najafi, Rezvan
    JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (02) : 1313 - 1325
  • [3] Therapy monitoring and management of adverse events in PD-1/PD-L1 immune checkpoint inhibition
    Oppel-Heuchel, H.
    Grimm, M. -O.
    UROLOGE, 2016, 55 (05): : 677 - 688
  • [4] Biomarkers in immune checkpoint inhibition therapy for cancer patients: what is the role of lymphocyte subsets and PD1/PD-L1?
    Puneet Singh
    Paul de Souza
    Kieran F. Scott
    Bruce M. Hall
    Nirupama D. Verma
    Therese M. Becker
    James W. T. Toh
    Mila Sajinovic
    Kevin J. Spring
    Translational Medicine Communications, 4 (1)
  • [5] Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
    Akinleye, Akintunde
    Rasool, Zoaib
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2019, 12 (01)
  • [6] Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
    Akintunde Akinleye
    Zoaib Rasool
    Journal of Hematology & Oncology, 12
  • [7] Oral immune checkpoint antagonists targeting PD-L1/VISTA or PD-L1/Tim3 for cancer therapy
    Sasikumar, Pottayil
    Sudarshan, N. S.
    Gowda, Nagaraj
    Samiulla, D. S.
    Ramachandra, Raghuveer
    Chandrasekhar, T.
    Adurthi, Sreenivas
    Mani, Jiju
    Nair, Rashmi
    Singh, Sharad
    Dhudashia, Amit
    Gowda, Nagesh
    Ramachandra, Murali
    CANCER RESEARCH, 2016, 76
  • [8] PD-L1 and Emerging Biomarkers in Immune Checkpoint Blockade Therapy
    Cottrell, Tricia R.
    Taube, Janis M.
    CANCER JOURNAL, 2018, 24 (01): : 41 - 46
  • [9] PD-1/PD-L1 Immune Checkpoint Inhibition with Radiation in Bladder Cancer: In Situ and Abscopal Effects
    Rompre-Brodeur, Alexis
    Shinde-Jadhav, Surashri
    Ayoub, Mina
    Piccirillo, Ciriaco A.
    Seuntjens, Jan
    Brimo, Fadi
    Mansure, Jose Joao
    Kassouf, Wassim
    MOLECULAR CANCER THERAPEUTICS, 2020, 19 (01) : 211 - 220
  • [10] Phytochemicals in regulating PD-1/PD-L1 and immune checkpoint blockade therapy
    Zhang, Qi
    Yang, Chenying
    Gao, Xingsu
    Dong, Ju
    Zhong, Caiyun
    PHYTOTHERAPY RESEARCH, 2024, 38 (02) : 776 - 796
12345